Breakthroughs in Leveraging Biomarkers for Oncology

Accelerating Solutions for Cancer Diagnostics and Therapeutics

USD 4,950

* Required Fields

USD 4,950

PAY BY INVOICE

Be the first to review this product

Predictive biomarkers are used to provide the best treatment indication with the greater probability of response to a certain specific chemotherapeutic agent, also considering treatment-related side effects. Prognostic biomarkers are used to identify patients with different clinical outcomes associated with somatic mutations, alterations in DNA methylation, germline polymorphisms, serum cytokine levels, expression of micro-RNA (miRNA) as well as circulating tumor cells (CTCs) in blood. Therefore, the precise identification of highly specific and sensitive biomarkers corresponding to certain clinical outcomes or antitumor effects constitutes one of the most crucial tasks in cancer research and treatment.

This research service depicts how biomarkers research has remarkably progressed in oncology and accelerates novel therapeutics discovery and development. In fact, recent biomarker research has outstandingly progressed and assisted early drug discovery and development by providing novel molecular-targeting agents in the field of oncology.

Table of Contents

1.0 Executive Summary1.1 Research Scope – Breakthroughs in Leveraging Biomarkers1.2 Research Focus – New Trends in Immuno-Oncology Biomarkers1.3 Research Framework – Predictive and Prognostic Biomarkers1.4 Research Methodology – The Frost & Sullivan Core Value1.5 Research Methodology – The Five Steps Toward Success1.6 Key Facts and Findings – The Global Picture in Numbers2.0 Industry Features and Future Concepts2.1 Key Elements of Analysis – The ‘Ideal Biomarker’ Concept2.2 Oncology Biomarkers Value Chain – Overall Landscape2.3 Key Elements of Analysis: Oncology Accelerated Pathway2.4 Key Elements of Analysis – Biomarker Stratification2.5 Key Elements of Analysis – Business and Processes2.6 Key Elements of Analysis – Emerging Business Models 2.7 Value Chain Interactive Model and Elements of Interaction2.8 Product Development and Commercialization2.9 Product Development and Commercialization – Time to Market2.9 Product Development and Commercialization – Time to Market (Continued)3.0 Technology Snapshot and Trends3.1 Emerging Technological Landscape for Oncology Biomarkers3.2 Proteomic Markers Expected to Transform the Future of Precision Oncology3.3 Nucleic Acid Biomarkers Likely to Dominate Screening and Predictive Applications in Clinical Oncology3.4 Emerging Metabolomic Profiling Assays May Facilitate Enhanced Cancer Diagnosis and Prognosis4.0 Emerging Innovation Landscape4.1 Redefining Oncology Diagnostics Through Comprehensive Biomarkers Assays4.2 Proteomic Markers for Precision Oncology Applications4.3 Recent Advances in Genomic Oncology Biomarker Technologies4.4 Precision Oncology Likely to be an Important Emerging Trend5.0 Analysis of Biomarkers by Cancer Indications5.1 Molecular Markers Impact Diagnosis and Management of Key Cancer Indications5.2 Diagnosis and Efficacy are the Key Application Areas for Breast Cancer Biomarkers5.3 Genomic and Biochemical Markers Lead Diagnostic and Efficacy Applications in the Lung Cancer Industry5.4 Colorectal Cancer Markers Aid Diagnostic and Prognostic Applications5.5 Biomarkers for Prostate Cancer Lead Diagnostic and Efficacy Applications5.6 Emerging Cervical Cancer Biomarkers Likely to be Useful as Therapeutic Targets6.0 Market Potential and Intellectual Property6.1 Oncology Biomarkers Impact Global Cancer Diagnostics Market6.2 North America Leads the Global Oncology Biomarkers Market6.3 Lung and Breast Cancer Biomarkers Present Largest Global Market Opportunities6.4 Defining Patent Research Scope and Search Concepts for Oncology Biomarkers6.5 Roche and Immatics Lead Patent Landscape for Oncology Biomarkers6.6 US Dominates the Global Blockchain Patent Portfolio Distribution for Oncology Biomarkers6.7 Rising Patent Publication Trend for ancer Biomarkers7.0 Growth Opportunities and Companies to Action7.1 Growth Opportunities – Leveraging Proteomic Markers for Companion Diagnostic Platforms7.2 Growth Opportunities – Nucleic Acid Biomarkers Fuel Precision Oncology Advancement7.3 Growth Opportunities – Metabolomic Markers Likely to be of Growing Importance in Cancer Therapy7.4 Strategic Imperatives for Success and Growth 8.0 Appendix8.1 Oncology Biomarkers Database: Critical Studies and Trials8.2 Key Industry Influencers 8.2 Key Industry Influencers (continued)8.2 Key Industry Influencers (continued)8.2 Key Industry Influencers (continued)8.2 Key Industry Influencers (continued) Legal Disclaimer




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 08-Dec-17

Region : Global

Release Date : 08-Dec-17

Region : Global

Release Date : 01-Dec-17

Region : Global

Release Date : 29-Nov-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.